Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer

References

• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label Phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. doi:10.1016/S0140-6736(17)31601-X
   PubMed Web of Science ®Google Scholar
• Betof WA, Palmer JS, Shoushtari AN, et al. Long-Term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020;38(15):1655–1663. doi:10.1200/JCO.19.01464
   PubMedGoogle Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757. doi:10.1016/S0140-6736(17)33297-X
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Ferris RL, Blumenschein GJ, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18(8):1104–1115. doi:10.1016/S1470-2045(17)30421-7
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Dawe DE, Harlos CH, Juergens RA. Immuno-oncology—the new paradigm of lung cancer treatment. Curr Oncol. 2020;27(Suppl 12):S78–S86. doi:10.3747/co.27.5183
   PubMedGoogle Scholar
• Larkin J, Minor D, D’Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, Open-Label Phase III trial. J Clin Oncol. 2018;36(4):383–390. doi:10.1200/JCO.2016.71.8023
   PubMed Web of Science ®Google Scholar
• Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC—update from PACIFIC. J Thorac Oncol. 2020;15(2):288–293. doi:10.1016/j.jtho.2019.10.002
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–627. doi:10.1016/j.jtho.2019.12.109
   PubMed Web of Science ®Google Scholar
• Travert C, Barlesi F, Greillier L, Tomasini P. Immune oncology biomarkers in lung cancer: an overview. Curr Oncol Rep. 2020;22(11):107. doi:10.1007/s11912-020-00970-3
   PubMed Web of Science ®Google Scholar
• Wang X, Wang F, Zhong M, Yarden Y, Fu L. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020;19(1):81. doi:10.1186/s12943-020-01200-x
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi:10.1158/1078-0432.CCR-16-1741
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced Non-Small cell lung cancer treated with PD-1/PD-L1 inhibitors or with Single-Agent chemotherapy. JAMA Oncol. 2018;4(11):1543–1552. doi:10.1001/jamaoncol.2018.3676
   PubMed Web of Science ®Google Scholar
• Lin Z, Zhang Y, Zhang L. Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non-small cell lung cancer. Cancer Commun. 2020;40(8):370–373. doi:10.1002/cac2.12070
   Web of Science ®Google Scholar
• Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081
   PubMed Web of Science ®Google Scholar
• Fang W, Chen Y, Sheng J, et al. Association between PD-L1 expression on tumour-infiltrating lymphocytes and overall survival in patients with gastric cancer. J Cancer. 2017;8(9):1579–1585. doi:10.7150/jca.18729
   PubMed Web of Science ®Google Scholar
• Ferte C, Fernandez M, Hollebecque A, et al. Tumor growth rate is an early indicator of antitumor drug activity in Phase I clinical trials. Clin Cancer Res. 2014;20(1):246–252. doi:10.1158/1078-0432.CCR-13-2098
   PubMed Web of Science ®Google Scholar
• Saada-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605–1611. doi:10.1093/annonc/mdx178
   PubMed Web of Science ®Google Scholar
• Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242–4250. doi:10.1158/1078-0432.CCR-16-3133
   PubMed Web of Science ®Google Scholar
• Wu Q, Xu Y, Zhang KJ, Jiang SM, Zhou Y, Zhao Y. A clinical model for the prediction of acute exacerbation risk in patients with idiopathic pulmonary fibrosis. Biomed Res Int. 2020;2020:8848919. doi:10.1155/2020/8848919
   PubMed Web of Science ®Google Scholar
• Kim CG, Kim KH, Pyo KH, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104–1113. doi:10.1093/annonc/mdz123
   PubMed Web of Science ®Google Scholar
• Lo RG, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res. 2019;25(3):989–999. doi:10.1158/1078-0432.CCR-18-1390
   PubMed Web of Science ®Google Scholar
• Locker GJ, Kapiotis S, Veitl M, et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol. 1999;105(4):912–919. doi:10.1046/j.1365-2141.1999.01453.x
   PubMed Web of Science ®Google Scholar
• Richard V, Bernier M, Themelin L, Bron D, Sculier JP. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Ann Oncol. 1991;2(1):67–68. doi:10.1093/oxfordjournals.annonc.a057827
   PubMed Web of Science ®Google Scholar
• Curti BD, Longo DL, Ochoa AC, et al. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol. 1993;11(4):652–660. doi:10.1200/JCO.1993.11.4.652
   PubMed Web of Science ®Google Scholar
• Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer Am Cancer Soc. 1994;73(6):1621–1624. doi:10.1002/1097-0142(19940315)73:6<1621::aid-cncr2820730613>3.0.co;2-e
   Google Scholar
• Buechner J, Grupp SA, Hiramatsu H, et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021;5(2):593–601. doi:10.1182/bloodadvances.2020002757
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, Phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi:10.1016/S1470-2045(17)30624-1
   PubMed Web of Science ®Google Scholar
• Kida W, Nakaya M, Ito A, Kozai Y, Bingo M. A case of acquired factor v inhibitor following nivolumab administration. Cureus. 2022;14(1):e21670. doi:10.7759/cureus.21670
   PubMed Web of Science ®Google Scholar
• Abbas M, Kassim SA, Wang ZC, Shi M, Hu Y, Zhu HL. Clinical evaluation of plasma coagulation parameters in patients with advanced-stage non-small cell lung cancer treated with palliative chemotherapy in China. Int J Clin Pract. 2020;74(12):e13619. doi:10.1111/ijcp.13619
   PubMed Web of Science ®Google Scholar
• Shu YJ, Weng H, Bao RF, et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. Bmc Cancer. 2014;14:566. doi:10.1186/1471-2407-14-566
   PubMed Web of Science ®Google Scholar
• Geng C, Yang G, Wang H, Zhang Z, Zhou H, Chen W. The prognostic role of prothrombin time and activated partial thromboplastin time in patients with newly diagnosed multiple myeloma. Biomed Res Int. 2021;2021:6689457. doi:10.1155/2021/6689457
   PubMed Web of Science ®Google Scholar
• Suzuki T, Shimada H, Nanami T, et al. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patients with gastric cancer. Surg Today. 2016;46(12):1394–1401. doi:10.1007/s00595-016-1339-z
   PubMed Web of Science ®Google Scholar
• Dirix LY, Oeyen S, Buys A, et al. Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer. Breast Cancer Res Treat. 2022;192(3):583–591. doi:10.1007/s10549-021-06484-1
   PubMed Web of Science ®Google Scholar
• Huang W, Li C, Wang Z, et al. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci China Life Sci. 2020;63(11):1678–1687. doi:10.1007/s11427-020-1733-4
   PubMed Web of Science ®Google Scholar
• Kas B, Talbot H, Ferrara R, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for Non-Small cell lung cancer. JAMA Oncol. 2020;6(7):1039–1046. doi:10.1001/jamaoncol.2020.1634
   PubMed Web of Science ®Google Scholar
• Matos I, Martin-Liberal J, Garcia-Ruiz A, et al. Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-19-2226
   Google Scholar
• Klempner SJ, Fabrizio D, Bane S, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2019. doi:10.1634/theoncologist.2019-0244
   Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/s41571-019-0218-0
   PubMed Web of Science ®Google Scholar